Literature DB >> 27552825

Serum Potassium Profile and Associated Factors in Incident Peritoneal Dialysis Patients.

Ying Liu1, Ben-Chung Cheng, Wen-Chin Lee, Lung-Chih Li, Chih-Hsiung Lee, Wen Xiu Chang, Jin-Bor Chen.   

Abstract

BACKGROUND/AIMS: Abnormal potassium profiles are common in peritoneal dialysis (PD) patients. We studied the factors associated with serum potassium profiles in incident PD patients.
METHODS: Patients were enrolled from two hospital-facilitated PD centers from May 2013 to May 2016 and January 2009 to December 2015. A total of 319 incident PD patients were examined for factors associated with serum potassium profile. Average serum potassium levels were obtained for analysis during the first 3 months after PD initiation. Clinically factors and parameters associated with PD were assessed by logistic regression.
RESULTS: There were 168 men and 151 women (mean age, 50.8 years). Blood urea nitrogen (BUN), creatinine (Cr), and intact parathyroid hormone levels were significantly increased in patients in the higher serum potassium group. There were no significant risk factors for hypokalemia, including sex, age, diabetes, blood examination parameters, medication use, or PD-related parameters by multivariate logistic regression analysis. BUN (adjusted odds ratio [OR] 1.02, 95% CI 1.01-1.03, p = 0.001) and Cr (adjusted OR 1.08, 95% CI 1.01-1.16, p = 0.029) levels were significant risk factors for hyperkalemia by multivariate logistic regression analysis.
CONCLUSION: Hyperkalemia and blood BUN and Cr levels were significantly associated in incident PD patients.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27552825     DOI: 10.1159/000443457

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  1 in total

1.  Hyperkalemia in chronic peritoneal dialysis patients.

Authors:  Andrew B Elliott; Karim M M Soliman; Michael E Ullian
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.